Quick Search 
Drugs of the Future
Register or sign in

Volume 30, Issue 8, August 2005, Pages 765-869
Treatment of pulmonary arterial hypertension, Endothelin ETA receptor antagonist.
Sorbera, L.A., Castaner, J.
Drugs Fut 2005, 30(8): 765
Summary | Full Text: HTMLPDF 
 Canertinib Dihydrochloride.
Oncolytic drug, HER (ErbB) inhibitor.
McIntyre, J.A., Castaner, J., Leeson, P.A.
Drugs Fut 2005, 30(8): 771
Summary | Full Text: HTMLPDF 
 Sugammadex Sodium.
Agent for reversal of neuromuscular blockade.
McIntyre, J.A., Castaner, J.
Drugs Fut 2005, 30(8): 780
Summary | Full Text: HTMLPDF 
 Sunitinib Malate.
Oncolytic drug, Multitargeted tyrosine kinase inhibitor.
McIntyre, J.A., Castaner, J.
Drugs Fut 2005, 30(8): 785
Summary | Full Text: HTMLPDF 
 PAR2 as a target for gastric mucosal protection.
Nishikawa, H., Kawabata, a.
Drugs Fut 2005, 30(8): 793
Summary | Full Text: HTMLPDF 
 Neuraminidase as a target for drugs for the treatment of influenza.
Liu, A-L., Wang, Y-T., Du, G-H.
Drugs Fut 2005, 30(8): 799
Summary | Full Text: HTMLPDF 
 The role of cannabinoids in preventing the neurodegenerative process occurring in Alzheimer's disease.
De Ceballos, M.L., Guzman, M.
Drugs Fut 2005, 30(8): 807
Summary | Full Text: HTMLPDF 
Annual Update 2004/2005
 Treatment of dermatological disorders.
N.E. Mealy, M. Bayés
Drugs Fut 2005, 30(8): 815
Full Text: PDF 

© 2020 Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy